Pfizer-BioNTech Seeks Approval For An Additional Third Dose Of Its COVID-19 Vaccine

Precautionary Dose Of Covid 19 Vaccine, Precautionary Dose Of Covid Vaccine, vaccine certificate compulsory, covid-19 vaccination of children ,Children COVID Vaccine Registration ,third vaccine dose, Covaxin For Kids, COVID in fully vaccinated peopleThird COVID-19 Vaccine Dose, Johnson & Johnson’s Vaccine, Covid vaccine trial on children, viral shedding, comirnaty, Sanofi-GSK COVID-19 vaccine, COVID vaccine her immunity, Delta Plus Variant Escape Vaccines, Johnson and Johnson vaccine ,Johnson and Johnson vaccine ,Trials Of Covavax On Children, Janssen Vaccine, janssen-vaccine, Heart Inflammation Risk Warning, pfizer vaccine india ,Best COVID Vaccine, mRNA COVID-19 vaccine, Pfizer vaccine for children, Punjab Students Planning To Go Abroad ,vaccine free ,COVID-19 vaccine after effect Pfizer and BioNTech Vaccine For Children, COVID vaccine start working, Covaxin trials on children ,Two COVID-19 Vaccine Doses Same Day, Pfizer-BioNTech Vaccine For Adolescents, slot for COVID-19 vaccination ,Moderna Pfizer Turns Down States Vaccine,India-Pfizer ,vaccine for children ,Sputnik Light ,Delayed Second Pfizer COVID-19 Shot, Pfizer Vaccine, rare COVID vaccine side-effects, Biological E. Vaccine Candidate, valneva vaccine, woman hates needles , Pfizer Donates DrugsVaccination for pregnant women ,COVAXIN ,COVID-19 reinfection ,co-win ,vaccine registration ,COVID-19 Vaccine For Below 18 Years, Free COVID-19 Vaccination ,Covishield Vaccine Open Market Price, Free COVID-19 vaccine ,COVID19 Vaccination Phase 3 ,18 years above eligible ,Priority Vaccines For Journalists ,Sputnik V Vaccine ,anti-rabies vaccine ,double shots of covid-19 vaccine ,100-Year-Old Woman vaccinated ,Bollywood stars COVID-19 vaccine ,Germany suspends AstraZeneca, After effects of COVID-19 infection ,Oxford Vaccine Europe Ban, Johnson Vaccine, cowin app children registration, What Is Corbevax
Pfizer-BioNTech seeks approval for third dose of Comirnaty vaccine: According to a statement by Pfizer-BioNTech, the company’s COVID-19 vaccine Comirnaty may require a third dose to work more efficiently against the original strain of the coronavirus. Interim data from an ongoing trial on the vaccine shows that the additional dose of the vaccine is expected to provide better protection against the Beta and Delta variant of the virus, first found in South Africa and India respectively.

The data showed that compared to the first two doses alone, a third dose of the vaccine can increase antibody levels about five to 10 times higher against these variants. In view of the interim data, the company announced on Thursday, July 8 that it will seek regulatory approval for the third dose of their COVID-19 vaccine as it will provide better protection against the virus.

The third dose of the vaccine might be needed within six to 12 months after the full vaccination for complete protection against the virus. The company is also working on a vaccine specific for the Delta variant and the first batch of it has already been manufactured at the company’s facility in Mainz, Germany.

The decision to include a third dose of the COVID-19 vaccine was taken after a study published in the journal “Nature” showed that a single shot of the AstraZeneca and Pfizer-BioNTech COVID-19 vaccine barely induces any antibodies against the Delta variant of the coronavirus.

According to initial studies done on the vaccine, it was shown that after two doses, it provides 94 percent protection against early variants however, the efficacy slipped against the Delta variant. Meanwhile, the central government of India had announced on June 25 that the country is conducting the first-ever study to find the effectiveness of COVID-19 vaccines of the Delta Plus variant.

Earlier this week, the Israeli government also spoke about the efficiency of the vaccine and said that Pfizer’s COVID-19 vaccine was reportedly dropping in efficacy after six months of taking the shot. Israel’s health ministry’s data also shows that between June 6 and early July, the vaccine only protected 64 per cent of the country’s people against the virus, which was earlier reported to be 94 per cent.

We request you to support our award-winning journalism by making a financial contribution towards our efforts. Your funds will ensure we can continue to bring you amazing stories of women, and the impact they are making and spotlight half the country's population because they deserve it.

By proceeding, you are agreeing to our Terms of Service .View our FAQs and Support page .